Dirk Winkler

TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.

TL;DR: CLL with TP53 mutation carries a poor prognosis regardless of the presence of 17p deletion when treated with F-based chemotherapy, and patients with TP 53 mutation should be considered for alternative treatment approaches.

TL;DR: Predictive marker analysis identified an interaction of NOTCH1 mutational status and treatment in that rituximab failed to improve response and survival in patients with NotCH1(mut).

TL;DR: Chemoimmunotherapy with BR is effective and safe in patients with previously untreated CLL, and 90.5% of patients were alive.

TL;DR: The de-monstration of clonal evolution under selective pressure supports the biologic significance of TP53 mutations in CLL and suggests that there may be patients where this treatment is potentially harmful.